48,390 Shares in AstraZeneca Plc $AZN Bought by Lido Advisors LLC

Lido Advisors LLC bought a new position in shares of AstraZeneca Plc (NYSE:AZN) in the third quarter, Holdings Channel reports. The fund bought 48,390 shares of the company’s stock, valued at approximately $7,814,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of AZN. Aries Wealth Management raised its stake in AstraZeneca by 1.3% in the 3rd quarter. Aries Wealth Management now owns 4,546 shares of the company’s stock worth $741,000 after purchasing an additional 60 shares in the last quarter. Triumph Capital Management boosted its holdings in AstraZeneca by 32.6% in the 3rd quarter. Triumph Capital Management now owns 252 shares of the company’s stock valued at $41,000 after purchasing an additional 62 shares during the period. Claro Advisors Inc. grew its position in shares of AstraZeneca by 5.2% during the 3rd quarter. Claro Advisors Inc. now owns 1,247 shares of the company’s stock worth $201,000 after purchasing an additional 62 shares in the last quarter. Riversedge Advisors LLC grew its position in shares of AstraZeneca by 2.9% during the 3rd quarter. Riversedge Advisors LLC now owns 2,347 shares of the company’s stock worth $379,000 after purchasing an additional 67 shares in the last quarter. Finally, Veery Capital LLC grew its position in shares of AstraZeneca by 3.9% during the 3rd quarter. Veery Capital LLC now owns 1,857 shares of the company’s stock worth $300,000 after purchasing an additional 70 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Zacks Research upgraded shares of AstraZeneca from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Weiss Ratings raised AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 26th. Deutsche Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. CICC Research began coverage on AstraZeneca in a research note on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price objective on the stock. Finally, Nordea Equity Research raised AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $206.67.

AstraZeneca Trading Down 0.6%

AZN opened at $184.46 on Friday. The company’s 50 day moving average is $168.42 and its 200-day moving average is $180.21. AstraZeneca Plc has a 1-year low of $153.41 and a 1-year high of $212.71. The company has a current ratio of 1.01, a quick ratio of 0.79 and a debt-to-equity ratio of 0.51. The company has a market cap of $286.08 billion, a P/E ratio of 26.09, a PEG ratio of 1.44 and a beta of 0.24.

AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Friday, October 30th. The company reported $2.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19. The business had revenue of $16.21 billion during the quarter, compared to analysts’ expectations of $16 billion. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The firm’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.38 EPS. Equities research analysts predict that AstraZeneca Plc will post 10.22 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.